{"id":19283,"date":"2021-10-20T11:00:26","date_gmt":"2021-10-20T09:00:26","guid":{"rendered":"https:\/\/idibell.cat\/?p=19283"},"modified":"2021-10-19T16:31:00","modified_gmt":"2021-10-19T14:31:00","slug":"identifiquen-dos-farmacs-amb-activitat-antitumoral-en-models-preclinics-de-cancer-de-pleura-maligne","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/10\/identifiquen-dos-farmacs-amb-activitat-antitumoral-en-models-preclinics-de-cancer-de-pleura-maligne\/","title":{"rendered":"Identifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne"},"content":{"rendered":"<p>El mesotelioma pleural maligne (MPM) \u00e9s un c\u00e0ncer molt agressiu en el qual es desenvolupen c\u00e8l\u00b7lules canceroses en el revestiment intern del t\u00f2rax, la pleura. <strong>La causa principal d&#8217;aquesta malaltia \u00e9s l&#8217;exposici\u00f3 a l&#8217;amiant<\/strong>. Actualment, no hi ha cap ter\u00e0pia efectiva per aquells pacients que han deixat de respondre a la quimioter\u00e0pia convencional amb plat\u00ed o a la immunoter\u00e0pia.<\/p>\n<p>El grup de recerca precl\u00ednica i experimental dels tumors tor\u00e0cics (<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/prett\/\">PrETT<\/a>) de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO), coliderat pel <strong>Dr. Ernest Nadal<\/strong> i la <strong>Dra. Cristina Mu\u00f1oz<\/strong>, ha descrit que dos f\u00e0rmacs, pr\u00e8viament aprovats pel tractament de c\u00e0ncer de mama, disminueixen la proliferaci\u00f3 de les c\u00e8l\u00b7lules tumorals i allarguen l&#8217;esperan\u00e7a de vida en models animals de MPM.<\/p>\n<p>Els inhibidors, anomenats abemaciclib i palbociclib, actuen sobre dues prote\u00efnes reguladores de la divisi\u00f3 cel\u00b7lular, CDK4 i CDK6. En l&#8217;estudi, publicat al <a href=\"https:\/\/www.nature.com\/articles\/s41416-021-01547-y\"><em>British Journal of Cancer<\/em><\/a>, els investigadors demostren que <strong>aquests f\u00e0rmacs aturen la proliferaci\u00f3 de les c\u00e8l\u00b7lules tumorals<\/strong> i indueixen un estat latent anomenat senesc\u00e8ncia en models cel\u00b7lulars, i augmenten l&#8217;esperan\u00e7a de vida en models animals.<\/p>\n<p>&#8220;<em>Els nostres resultats recolzen la realitzaci\u00f3 d&#8217;assajos cl\u00ednics per avaluar l&#8217;efic\u00e0cia d&#8217;aquests compostos com a tractament de segona l\u00ednia en pacients que han desenvolupat resist\u00e8ncies a la quimioter\u00e0pia i ja no responen al tractament<\/em>&#8220;, comenta el <strong>Dr. Nadal<\/strong>.<\/p>\n<p>L&#8217;estudi tamb\u00e9 descriu que els f\u00e0rmacs estimulen el reconeixement de les c\u00e8l\u00b7lules tumorals per part del sistema immunitari com a dianes a atacar. &#8220;<em>L&#8217;activaci\u00f3 d&#8217;aquestes vies suggereix que els f\u00e0rmacs abemaciclib i palbociclib podrien ajudar a potenciar l&#8217;activitat de la immunoter\u00e0pia contra les c\u00e8l\u00b7lules tumorals<\/em>&#8220;, comenta la <strong>Dra. Elisabet Aliagas<\/strong>, primera autora del treball.<\/p>\n<p>&nbsp;<\/p>\n<h4>Els models <em>in vivo<\/em> i <em>in vitro<\/em><\/h4>\n<p>El treball ha analitzat la capacitat dels inhibidors de CDK4 i CDK6 d&#8217;aturar o disminuir la divisi\u00f3 cel\u00b7lular en <strong>cinc l\u00ednies cel\u00b7lulars comercials i en tres l\u00ednies prim\u00e0ries<\/strong> de c\u00e8l\u00b7lules obtingudes d&#8217;efusions pleurals de pacients amb MPM diagnosticat i tractats a l\u2019Hospital Universitari de Bellvitge o a l\u2019Institut Catal\u00e0 d\u2019Oncologia.<\/p>\n<p>A m\u00e9s, els investigadors en col\u00b7laboraci\u00f3 amb el <strong>Dr. Alberto Villanueva<\/strong> han utilitzat un model ortot\u00f2pic de ratol\u00ed, en el qual se li han implantat c\u00e8l\u00b7lules tumorals procedents de pacients amb MPM, i posteriorment s\u2019ha avaluat la resposta d&#8217;aquestes c\u00e8l\u00b7lules al tractament en un ambient que recapitula el que passa en els humans.<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigadors de l&#8217;IDIBELL i de l&#8217;ICO descriuen que inhibidors de les prote\u00efnes CDK4 i CDK6 aturen la proliferaci\u00f3 de c\u00e8l\u00b7lules tumorals i allarguen l&#8217;esperan\u00e7a de vida en models animals.<\/p>\n","protected":false},"author":8,"featured_media":19284,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,333],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-11 18:12:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19283"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=19283"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19283\/revisions"}],"predecessor-version":[{"id":19285,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19283\/revisions\/19285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/19284"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=19283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=19283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=19283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}